Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis

AIDS

Volumn 16, Issue 5, 2002, Pages 757-765

  Davidson, Michael ^a   Min, Yuan I ^a   Holbrook, Janet T ^a   Van Natta, Mark L ^a   Murphy, Robert ^b   Jabs, Douglas A ^a,c,e   Welch, William ^d   Meinert, Curtis L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AIDS; Cytomegalovirus retinitis; Filgrastim; Granulocyte macrophage colony stimulating factor; Neutrophil count

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CLARITHROMYCIN; COTRIMOXAZOLE; FOSCARNET; GANCICLOVIR; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETINITIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; CHEMOTHERAPY, ADJUVANT; CYTOMEGALOVIRUS RETINITIS; FEMALE; FILGRASTIM; HOSPITALIZATION; HUMANS; MALE; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 0037192552     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00011     Document Type: Article

References (31)

1. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection
2. Neutropenia and bacterial infection in acquired immunodeficiency syndrome
3. Combined ganciclovir and recombinant granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients
4. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind placebo controlled trial
5. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection
6. Mechanisms of cytopenla in human immunodeficiency virus infection
7. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
8. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients
9. Outcomes of granulocyte colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus
10. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV suppression
11. Filgrastim (G-CSF) use is asociated with prolonged survival in AIDS-patient with leukopenia and CD4 cells < 50 × 106/I
12. 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: A summary
13. Combination foscarnet ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial
14. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome
15. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinltis Trial 1. Rationale, design, and methods
16. Catheter complications in AIDS patients treated for cytomegalovirus retinitis
17. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California
18. Recurrent pneumococcal bacteremia. A warning of immunodeficiency
19. Bacteremia in HIV-positive and AIDS patients: Incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment
20. Estimation of the effect of neutropenia on rates of clinical bacteraemia in HIV-infected patients
21. Indwelling central venous catheter infections in patients with acquired immune deficiency syndrome
22. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease
23. Filgrastim restores interleukin-2 in blood from patients with advanced human immunodeficiency virus infection
24. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival
25. Intralymphatic interleukin-2 combination with zidovudine for the therapy of patients with AIDS
26. Outpatient continuous intravenous Interleukin-2 or subcutaneous polyethylene glycol-modified Interleukin-2 in human immunodeficiency virus infected patients: A randomized controlled, multicenter study
27. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment
28. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy
29. Pneumocystis prophylaxis and survival in patients with advanced human immunodeflciency virus infection treated with zidovudine
30. Frequency of risk factors of infectious complications in neutropenic patients infected with HIV
31. The influence of granulocyte colony- stimulating factor on HIV-1 RNA in patients with CMV retinitis